Metoprolol eye drops in the treatment of glaucoma a double-blind single-dose trial of a beta1-adrenergic bloking drug

F. E. Ros, C. L. Dake, N. J.D. Nagelkerke, E. L. Greve

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Abstract

A double-blind single-dose trial was performed on 13 patients with primary open-angle glaucoma. Metoprolol 1%, 2%, and 4% produced a median fall in IOP of 5.6, 5.4, and 6.8 mm Hg, respectively, in the treated eye. The differences in effect between the 1%, 2%, and 4% solutions were not statistically significant. There was no significant fall in IOP in the untreated eyes. There were no significant changes in blood pressure, pulse rate, or pupilary diameter. We could not detect any local objective or subjective side effects during the single-dose study. The clinical usefulness of metoprolol may be limited due to local toxic reactions after treatment with multiple doses. Furthermore, there is the problem of tachyphylaxis that could limit extended treatment with topical beta-adrenergic blocking drugs.

Original languageEnglish
Pages (from-to)247-254
Number of pages8
JournalAlbrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie
Volume206
Issue number4
DOIs
Publication statusPublished - Jun 1 1978

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Metoprolol eye drops in the treatment of glaucoma a double-blind single-dose trial of a beta1-adrenergic bloking drug'. Together they form a unique fingerprint.

Cite this